List of Excipients in Branded Drug VYXEOS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Jazz Pharmaceuticals Inc	VYXEOS	(daunorubicin and cytarabine) liposome	68727-745	CHOLESTEROL	2028-03-30
Jazz Pharmaceuticals Inc	VYXEOS	(daunorubicin and cytarabine) liposome	68727-745	COPPER GLUCONATE	2028-03-30
Jazz Pharmaceuticals Inc	VYXEOS	(daunorubicin and cytarabine) liposome	68727-745	DISTEAROYLPHOSPHATIDYLCHOLINE, DL-	2028-03-30

Vyxeos Excipient Strategy and Commercial Opportunities: Liposomal Formulation, Generic Risk, and Patent Considerations

Last updated: August 24, 2026

Vyxeos is a liposomal fixed-ratio combination of daunorubicin and cytarabine for adults with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes. Its commercial differentiation depends on the delivery system, not on a new active pharmaceutical ingredient. The formulation uses a defined phospholipid-cholesterol liposome containing cytarabine and daunorubicin at a 5:1 molar ratio, with copper gluconate and sucrose supporting drug loading, stability, and reconstitution.[1]

The primary commercial opportunity is therefore not a conventional excipient substitution. It is the development of alternative liposomal manufacturing, loading, lyophilization, stability, and scale-up technologies that preserve the critical quality attributes of the product. Generic or follow-on competitors face a higher technical barrier than competitors developing a simple daunorubicin-cytarabine admixture.

What excipients are used in Vyxeos?

Vyxeos is supplied as a lyophilized powder for reconstitution and intravenous infusion. The inactive ingredients identified in the FDA prescribing information are:

Excipient or formulation component	Functional role
Distearoylphosphatidylcholine, or DSPC	Structural phospholipid forming the liposomal bilayer
Distearoylphosphatidylglycerol, or DSPG	Anionic phospholipid contributing to membrane charge and drug retention
Cholesterol	Controls membrane packing, rigidity, permeability, and stability
Copper gluconate	Provides copper for formation of the copper-drug complex used in remote loading
Sucrose	Lyoprotectant and bulking agent for the freeze-dried product
Cytarabine and daunorubicin	Active ingredients encapsulated in the liposome

The product contains the two active ingredients at a fixed 1:5 daunorubicin-to-cytarabine molar ratio. This ratio is a product-defining attribute because the clinical development program evaluated the combined formulation rather than independent administration of the two drugs.[1]

How do the Vyxeos excipients support drug loading?

The formulation uses a transmembrane copper gradient to load the active ingredients into the liposomes. Copper gluconate is central to this process. The liposome interior contains copper, while the external formulation environment supports drug entry and formation of poorly soluble copper-drug complexes inside the vesicle.

This approach is materially different from passive encapsulation. Passive encapsulation generally produces lower loading efficiency and greater variability. Remote loading can improve encapsulation, maintain a high internal drug concentration, and reduce premature release.

DSPC, DSPG, and cholesterol create a relatively rigid bilayer. The high transition temperature of DSPC supports physical stability at storage and physiological temperatures. DSPG contributes a negative surface charge that can affect liposome aggregation, drug retention, and interaction with plasma proteins. Cholesterol reduces membrane permeability and helps stabilize the bilayer.

Sucrose protects the liposome during freezing and drying. It can replace water around phospholipid head groups during lyophilization, reducing membrane disruption during manufacture and reconstitution.

What is the commercial value of Vyxeos’s excipient system?

The excipient system has value because it is integrated with the manufacturing process. A competitor cannot necessarily replace one excipient while preserving the same drug loading, particle-size distribution, release profile, sterility profile, and clinical performance.

The principal value drivers are:

1. High drug loading through copper-mediated remote loading.
2. Maintenance of the 5:1 cytarabine-daunorubicin ratio.
3. Controlled release after intravenous administration.
4. Improved handling relative to separate conventional drug products.
5. A lyophilized presentation that supports product stability and distribution.
6. Potential reduction in formulation variability between doses.

The formulation also creates barriers for contract manufacturers and excipient suppliers. A supplier must demonstrate pharmaceutical-grade consistency for phospholipids, cholesterol, copper salts, and sucrose. Changes in lipid purity, oxidation, hydrolysis, particle size, or residual solvents can affect product quality.

What formulation patents protect Vyxeos?

Vyxeos protection is likely to rely more heavily on liposomal composition, drug-loading methods, manufacturing processes, and use claims than on patents covering the individual excipients. DSPC, DSPG, cholesterol, copper gluconate, and sucrose are established pharmaceutical materials and generally do not provide meaningful standalone exclusivity.

Potential claim categories include:

Claim category	Commercial relevance
Liposome composition	Defines the lipid mixture, drug ratio, and internal components
Remote-loading process	Protects copper-gradient formation and drug encapsulation
Drug-to-lipid ratio	Can limit design-around options if clinically important
Particle-size distribution	May connect formulation structure with pharmacokinetic performance
Lyophilization cycle	Protects the drying and reconstitution process
Stability profile	May support claims directed to storage or reduced drug leakage
Treatment method	Covers use in therapy-related AML or AML with myelodysplasia-related changes
Combination administration	May address dosing or administration of the fixed-ratio product

The patent analysis must distinguish between patents assigned to the original developer, Celator Pharmaceuticals, and later rights held by Jazz Pharmaceuticals or related entities. Patent term, terminal disclaimers, patent-term adjustment, patent-term extension, and Orange Book listing status can change the effective exclusivity analysis.

A third-party excipient patent is less likely to block a Vyxeos competitor than a patent claiming the complete liposome or the loading process. The strongest formulation claims would normally be those that combine the lipid composition, active-ingredient ratio, loading method, and finished-product characteristics.

When does Vyxeos lose regulatory exclusivity?

Vyxeos received FDA approval on August 3, 2017, under NDA 209401.[1] Its regulatory protection has several components:

Protection type	Relevance to Vyxeos
New chemical entity exclusivity	Generally five years from approval if applicable
Orphan-drug exclusivity	Seven years for the protected orphan indication
Patent protection	Depends on issued claims and expiration dates
Pediatric exclusivity	Adds six months only if FDA requirements are met
ANDA exclusivity	Relevant to future generic applicants

The five-year NCE period would generally have ended in 2022. Orphan-drug exclusivity for the approved AML indication could extend through approximately 2024, subject to the precise orphan designation and scope of the protected indication. Orphan exclusivity does not prevent every competing product. It blocks FDA approval of the same drug for the same indication unless the competitor demonstrates clinical superiority or another statutory exception applies.

Vyxeos is a small-molecule drug product, not a biologic. Biosimilar exclusivity does not apply. A follow-on product would generally proceed through the ANDA pathway if FDA determines that the product can meet the requirements for pharmaceutical equivalence and bioequivalence. If the liposomal product cannot be adequately characterized through standard methods, a 505(b)(2) route may be considered, depending on the proposed product and FDA’s assessment.

What is the Orange Book status of Vyxeos?

Vyxeos is listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, under NDA 209401.[2] Orange Book analysis should address:

• Listed patents and their expiration dates.
• Whether each patent is identified as a drug-substance, drug-product, or method-of-use patent.
• Whether an ANDA applicant must submit a Paragraph IV certification.
• Whether any listed method-of-use patent can be carved out through a section viii statement.
• Whether the relevant patent claims cover the liposome itself rather than only the approved indication.

A patent listed for a method of treating a specific AML population may be more susceptible to a label carve-out than a patent covering the composition of the drug product. A composition or formulation patent can present a broader launch barrier because a generic product may infringe through manufacture or sale even if its label omits a protected use.

What generic entry risks exist for Vyxeos?

Generic entry risk is higher after the expiration of regulatory exclusivities, but technical substitutability remains difficult. A competing product must address:

• Liposome size and size distribution.
• Encapsulation efficiency.
• Free-drug content.
• Internal copper concentration.
• Cytarabine and daunorubicin loading ratio.
• Lipid composition and purity.
• Drug-release kinetics.
• Reconstitution time.
• Osmolality and pH.
• Sterility and bacterial endotoxin limits.
• Stability after reconstitution.
• Particulate matter and aggregation.

The critical risk is that a product may match the nominal composition but fail to match the clinically relevant performance of the reference product. FDA guidance for liposome drug products emphasizes characterization of liposome structure, composition, drug loading, release, stability, and quality attributes.[3]

What Paragraph IV challenges could affect Vyxeos?

A Paragraph IV challenge could target any Orange Book-listed patent that remains relevant after regulatory exclusivity expires. The most commercially important challenge would likely involve a patent claiming the complete liposomal composition or a manufacturing method required to produce an equivalent product.

A successful Paragraph IV strategy could take several forms:

1. Noninfringement based on a different lipid ratio, loading process, or lyophilization cycle.
2. Invalidity based on anticipation or obviousness.
3. A section viii label carve-out for method-of-use claims.
4. A 505(b)(2) application with a differentiated formulation.
5. A complex generic strategy supported by comparative physicochemical testing.

The presence of an Orange Book patent does not establish that the patent is valid or enforceable. It does create litigation and launch-timing risk. An ANDA applicant providing a Paragraph IV certification can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework.[4]

How strong is the Vyxeos patent estate?

The estate is strongest where claims connect formulation composition with measurable product performance. Claims directed only to individual conventional excipients are comparatively weak because those materials are widely known and commercially available.

Strong claim areas

• Defined liposome architecture.
• Fixed 5:1 molar ratio.
• Copper-mediated remote loading.
• High encapsulation efficiency.
• Controlled leakage or release.
• Specific lipid ratios.
• Product stability after lyophilization.
• Manufacturing parameters that are difficult to reproduce without using the claimed process.

Weaker claim areas

• Use of sucrose as a lyoprotectant without additional limitations.
• Use of cholesterol in a liposome.
• Use of DSPC or DSPG without a defined combination or performance limitation.
• Broad claims to daunorubicin and cytarabine co-delivery where prior liposomal anthracycline and nucleoside formulations are relevant.

The estate’s practical strength will depend on claim construction, prosecution history, written-description support, enablement, and the ability to prove infringement through finished-product testing or manufacturing records.

What excipient opportunities exist for suppliers and competitors?

The commercial opportunity is concentrated in enabling technologies rather than commodity excipient sales.

High-value excipient opportunities

Phospholipid quality and supply

Pharmaceutical-grade DSPC and DSPG suppliers can compete on oxidation control, hydrolysis limits, batch consistency, documentation, and long-term supply security. Lipid raw materials are vulnerable to degradation and can require specialized packaging, low-oxygen handling, and controlled storage.

Alternative lyoprotectants

Trehalose, mannitol, or combinations of sugars and polyols could be evaluated as alternatives to sucrose. Any substitution would require evidence that the liposome maintains size, encapsulation, release characteristics, and reconstitution performance.

Alternative internal salts

Competitors may explore other metal-ion or counterion systems for remote loading. Copper is closely linked to the Vyxeos loading mechanism, so alternatives could create a design-around opportunity. The regulatory burden would rise if the new internal chemistry changes pharmacokinetics, toxicity, or release.

Lipid oxidation inhibitors

Antioxidant strategies, inert-gas processing, improved container closure systems, and lower-temperature handling could reduce degradation of phospholipids. These approaches may generate process patents even when the core excipients remain unchanged.

Ready-to-use or improved reconstitution presentations

A liquid or more rapidly reconstituted presentation could improve pharmacy workflow. The commercial benefit would need to outweigh the stability, shipping, container-closure, and microbial-control challenges of eliminating the lyophilized format.

Targeted liposomal systems

A next-generation product could add a targeting ligand or alter surface properties to improve leukemia-cell delivery. Such a product would likely require new clinical evidence and could compete as a differentiated 505(b)(2) product rather than as a substitutable generic.

How does Vyxeos compare with conventional daunorubicin and cytarabine?

Attribute	Vyxeos	Conventional administration
Drug delivery	Single liposomal product	Separate drug products
Drug ratio	Fixed 5:1 molar ratio	Dose ratio can vary by regimen
Loading	Remote-loaded liposome	No liposomal encapsulation
Presentation	Lyophilized powder	Conventional injectable formulations
Formulation complexity	High	Lower
Generic substitution	Technically difficult	More established
Excipient importance	Central to product performance	Generally less decisive
Manufacturing barrier	High	Moderate

Vyxeos’s commercial position depends on preserving the clinical and operational value of the fixed-ratio liposomal product. A low-cost conventional daunorubicin-cytarabine regimen is not automatically substitutable for Vyxeos because the delivery system, exposure profile, dosing, and approved product characteristics differ.

What licensing deals and litigation affect Vyxeos?

Celator developed Vyxeos before Jazz Pharmaceuticals acquired Celator in 2016. Jazz obtained the Vyxeos business through that acquisition.[5] The principal licensing and transaction issue is therefore ownership transfer and control of the formulation and related intellectual property, rather than a widely disclosed excipient-specific licensing program.

No excipient-specific licensing deal should be assumed without reviewing the underlying patent assignments, supply agreements, and development contracts. For transaction diligence, the relevant documents are:

• Patent assignment records from Celator to Jazz.
• Exclusive development or commercialization agreements.
• Phospholipid and copper-salt supply contracts.
• Manufacturing and technology-transfer agreements.
• ANDA litigation filings.
• FDA Orange Book patent listings.
• Abbreviated new drug application approvals.

A litigation search should cover Jazz, Celator, Vyxeos, daunorubicin liposome, cytarabine liposome, DSPC, DSPG, copper-gradient loading, and relevant patent-family members in the United States, Europe, Canada, Japan, and other major markets.

What geographic coverage matters for Vyxeos excipient strategy?

The United States is the principal patent and generic-entry jurisdiction because FDA approval, Orange Book listings, Paragraph IV certifications, and Hatch-Waxman litigation determine the U.S. launch pathway.

Europe presents a different assessment. Patent rights are evaluated through European Patent Office prosecution and national validation, while marketing authorization and supplementary protection certificate issues are handled under European and national frameworks. Japan, Canada, Australia, and South Korea may have separate patent families, regulatory data-protection rules, and requirements for complex liposomal products.

Excipient suppliers should prioritize jurisdictions with:

• High AML treatment volumes.
• Strong oncology procurement markets.
• Local sterile manufacturing capacity.
• Established liposome development infrastructure.
• Active generic or 505(b)(2) competition.
• Enforceable process and formulation patents.

Key Takeaways

• Vyxeos is a complex liposomal combination of daunorubicin and cytarabine, not a conventional co-administration.
• DSPC, DSPG, cholesterol, copper gluconate, and sucrose are central to product manufacture and stability.
• Copper gluconate supports remote loading and is more strategically important than its status as an inactive ingredient suggests.
• The strongest competitive barriers are likely to involve the complete liposome, drug-loading process, fixed ratio, release profile, and lyophilization process.
• Biosimilar rules do not apply because Vyxeos is a small-molecule product.
• Generic competitors would face ANDA, 505(b)(2), patent, and complex-product characterization issues.
• Commercial opportunities are strongest in pharmaceutical-grade phospholipids, stability enhancement, alternative loading chemistry, lyophilization, and improved reconstitution.
• A conventional daunorubicin-cytarabine regimen is not automatically substitutable for Vyxeos.
• Any current patent-expiration or Paragraph IV conclusion requires review of the live Orange Book listing, issued patent claims, patent-term calculations, and litigation docket.

FAQs About Vyxeos Excipients and Commercial Strategy

Does Vyxeos contain PEGylated lipids?

The FDA prescribing information identifies DSPC, DSPG, cholesterol, copper gluconate, and sucrose. It does not identify a PEGylated lipid as an inactive ingredient.[1]

Can sucrose in Vyxeos be replaced with trehalose?

Potentially, but substitution would require comparative data covering liposome integrity, drug retention, reconstitution, stability, and release. The replacement could also affect regulatory comparability and patent-positioning analysis.

Is copper gluconate a patentable excipient opportunity for Vyxeos competitors?

Copper gluconate alone is unlikely to create a strong exclusionary position. Commercial value is more likely to arise from the copper-gradient loading method, internal copper concentration, loading conditions, or resulting product attributes.

Can a generic company use different phospholipids from Vyxeos?

A different lipid system may be possible, but it could prevent pharmaceutical equivalence and require a 505(b)(2) application or a more extensive development program. It may also avoid some composition claims while creating new clinical and regulatory obligations.

Is Vyxeos exposed to biosimilar competition?

No. Vyxeos contains small-molecule active ingredients and is regulated as a drug product rather than a biologic. Competitive entry would more likely involve an ANDA, a 505(b)(2) application, or a separately approved oncology product.

References

1. U.S. Food and Drug Administration. (2024). Vyxeos (daunorubicin and cytarabine) liposome for injection: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Food and Drug Administration. (2018). Liposome drug products: Chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation: Guidance for industry.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards.
5. Jazz Pharmaceuticals plc. (2016). Jazz Pharmaceuticals completes acquisition of Celator Pharmaceuticals.